USE OF Galectin-1 INHIBITOR IN PREPARATION OF DRUG FOR TREATING PULMONARY FIBROSIS

Abstract: provided is a use of a galectin-1 inhibitor in preparation of a drug for treating pulmonary fibrosis. taking silicosis model mice as a subject, administration of a galectin-1 inhibitor otx008 to silicosis mice can effectively alleviate the progression of pulmonary fibrosis. studies have shown that the lung function of mice with silicosis is improved significantly; transcription levels of inflammatory factors il-1� and il-6 in the lung tissue of silicosis mice are decreased, concentrations of il-1� and il-6 in the alveolar lavage fluid are also decreased, and the infiltration of inflammatory cells is decreased. in the lung tissue of silicosis mice, the transcription levels of fibrosis factors col-i and fn-1 are decreased, the collagen-specific amino acid hydroxyproline is decreased, the fibrosis lesions are decreased, and the degree of lesions is alleviated. therefore, the galectin-1 inhibitor can be used as a new treatment strategy for pulmonary fibrosis.

Inventor(s): Jing Wang, Meiyue Song, Jiaxin Wang, Xue Wang

CPC Classification: A61K31/165 (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms ; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles ; soap compositions ))

Search for rejections for patent application number 20250228801